Commentary
Podcast
Author(s):
Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, supported by Pfizer and Novartis, we had the pleasure of speaking with the panelists from OncLive’s inaugural Women in Oncology event, which took place during the 41st Annual Miami Breast Cancer Conference.
Stephanie L. Graff, MD, is the director of Breast Oncology at Lifespan Cancer Institute, as well as an associate professor of medicine at Brown University, both in Providence, Rhode Island.
Reshma L. Mahtani, DO, is a medical oncologist at Miami Cancer Institute and chief of Breast Medical Oncology at Baptist Health’s Wellness and Medical Complex in Florida.
Kelly E. McCann, MD, PhD, is a breast medical oncologist and an assistant clinical professor of medicine at the University of California, Los Angeles Health David Geffen School of Medicine.
Hope S. Rugo, MD, is the Winterhof Family Endowed Professor in Breast Cancer at the University of California San Francisco (UCSF), as well as a professor of medicine in the Division of Hematology and Oncology, director of Breast Oncology, director of Clinical Trials Education, and director of Cancer Infusion Services at the UCSF Helen Diller Family Comprehensive Cancer Center.
In our exclusive interview, Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they continue to encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by Pfizer and Novartis. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
2 Commerce Drive
Cranbury, NJ 08512